Equity Profile

TNGX

Tango Therapeutics, Inc.

Health CareBiotechnology$4.6B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product offerings.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TNGX Q2-2026 Earnings Preview

Context

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies. With a market cap of $5 billion, it operates in the health care sector, which is increasingly important as advancements in personalized medicine and targeted treatments gain traction.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+117.71%

Avg Stock Reaction

+2.19%

Last Quarter Recap

In Q1-2026, Tango reported an EPS of -$0.32, slightly missing expectations. The stock reacted positively, gaining 8.55% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Tango's upcoming earnings report, particularly given the company's recent performance. However, uncertainty remains due to the lack of analyst estimates.

Bull Case

If Tango can demonstrate significant progress in its clinical trials or better-than-expected revenue growth, it could lead to a strong positive reaction in the stock.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its pipeline, the stock could face downward pressure.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of ongoing clinical trials?

Investors will be closely watching for any advancements or setbacks in clinical trials, as these can significantly influence the company's future prospects.

How does the company plan to address its recent earnings performance?

Management's commentary on addressing past performance and future strategies will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of recent clinical trial advancements, which could lead to better-than-expected results this quarter.

Supporting Evidence

The stock has historically reacted positively to small beats, indicating that even minor improvements can drive significant gains.

The options market is pricing in a relatively low move compared to historical averages, suggesting that traders may be underestimating potential volatility.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around the company's ability to progress in its clinical trials and improve its financial performance.

Bull Confirmed If

Demonstrating a significant advancement in clinical trial results could confirm the bull case.

Bear Confirmed If

Failure to provide any positive updates on clinical trials or revenue could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±8.57%

Historical Avg

±14.0%

Pricing cheap

The options market is pricing in an 8.57% move, indicating that traders expect some volatility around the earnings announcement.

Options are pricing ±8.6% while TNGX has averaged ±14.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

1.1%

30d HV

93.8%

Calls (1K)P/C Ratio: 1.21Puts (13K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tango beats expectations, history suggests a potential stock increase of around 0.09%, confirming positive market sentiment.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may react moderately, reflecting uncertainty.

Miss

A miss could lead to a decline, with history suggesting an average drop of 5.68% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and any new data.
2Management's plans for future product launches or pipeline developments.
3Insights into revenue growth strategies and market expansion.
4Any commentary on partnerships or collaborations that could enhance growth.
5Management's perspective on industry trends and competitive landscape.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product offerings.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TNGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+117.71%

Avg Stock Reaction

+2.19%

Last Quarter Recap

In Q1-2026, Tango reported an EPS of -$0.32, slightly missing expectations. The stock reacted positively, gaining 8.55% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Tango's upcoming earnings report, particularly given the company's recent performance. However, uncertainty remains due to the lack of analyst estimates.

Bull Case

If Tango can demonstrate significant progress in its clinical trials or better-than-expected revenue growth, it could lead to a strong positive reaction in the stock.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its pipeline, the stock could face downward pressure.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of ongoing clinical trials?

Investors will be closely watching for any advancements or setbacks in clinical trials, as these can significantly influence the company's future prospects.

How does the company plan to address its recent earnings performance?

Management's commentary on addressing past performance and future strategies will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of recent clinical trial advancements, which could lead to better-than-expected results this quarter.

Supporting Evidence

The stock has historically reacted positively to small beats, indicating that even minor improvements can drive significant gains.

The options market is pricing in a relatively low move compared to historical averages, suggesting that traders may be underestimating potential volatility.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around the company's ability to progress in its clinical trials and improve its financial performance.

Bull Confirmed If

Demonstrating a significant advancement in clinical trial results could confirm the bull case.

Bear Confirmed If

Failure to provide any positive updates on clinical trials or revenue could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±8.57%

Historical Avg

±14.0%

Pricing cheap

The options market is pricing in an 8.57% move, indicating that traders expect some volatility around the earnings announcement.

Options are pricing ±8.6% while TNGX has averaged ±14.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

1.1%

30d HV

93.8%

Calls (1K)P/C Ratio: 1.21Puts (13K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tango beats expectations, history suggests a potential stock increase of around 0.09%, confirming positive market sentiment.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may react moderately, reflecting uncertainty.

Miss

A miss could lead to a decline, with history suggesting an average drop of 5.68% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and any new data.
2Management's plans for future product launches or pipeline developments.
3Insights into revenue growth strategies and market expansion.
4Any commentary on partnerships or collaborations that could enhance growth.
5Management's perspective on industry trends and competitive landscape.